Furthermore, we demonstrate that doxorubicin treatment increases DCAF13 expression in breast cancer cells, thereby promoting cancer cell migration and invasion, indicating that doxorubicin chemotherapy may increase the risk of metastasis of drug‐resistant breast cancer cells by increasing DCAF13 expression. The gene discussed is DCAF13; the disease is breast carcinoma.